Verismo Secures CLDN6 Target, Expands Solid Tumor CAR-T Pipeline
Second Targeted Binder Secured through Collaboration with UPenn
Initiation of Preclinical Development for CLDN6 Using KIR-CAR Platform
Expansion of Solid Tumor Indications Following Mesothelin
HLB Innovation's U.S. subsidiary, Verismo Therapeutics, announced on July 21 that it has secured a novel solid tumor-targeted binder through research collaboration with the University of Pennsylvania (UPenn) and will expand its next-generation KIR-CAR platform-based solid tumor pipeline.
Verismo has applied a targeted binder that recognizes claudin 6 (CLDN6) antigens on the surface of cancer cells to its KIR-CAR platform, initiating preclinical development targeting solid tumors that express CLDN6.
This CLDN6-targeted binder was discovered by the research team of Dr. Donald Siegel, co-founder and co-chair of the Scientific Advisory Board at UPenn’s Perelman School of Medicine, through a research support agreement with Verismo. It is the second targeted binder secured through collaboration with UPenn, following the DS191 applied to the hematological cancer CAR-T candidate 'SynKIR-310,' which is currently in phase 1 clinical trials.
CLDN6 is known to be expressed in various types of cancer but is limited in expression in normal adult tissue, making it an attractive emerging target for next-generation immuno-oncology therapies. Development is also underway for various therapeutic approaches such as CAR-T, antibody-drug conjugate (ADC), and bispecific antibodies.
Verismo plans to combine its proprietary CLDN6 binder with the multi-chain KIR-CAR platform to overcome the persistence limitations of existing CLDN6-targeted therapies and to develop cell therapies that improve anti-cancer immune responses in solid tumors.
Brian Kim, CEO of Verismo, stated, "Securing CLDN6 as a new target for solid tumors expands the application scope of the KIR-CAR platform," adding, "We will continue to broaden our pipeline to target a variety of solid tumors."
Hot Picks Today
"Auntie, When Will Dried Shredded Squid Return as a Side Dish?"...Once Vanished from Restaurants, Now Making a Comeback
- Monthly Salary Soars 3.7 Times from 8.25 Million Won to 30.59 Million Won... 86 Fair Trade Commission Retirees Join Law Firms Over 10 Years
- "Wait a Little Longer, Honey"... Why Samsung Electronics and SK hynix Employees' Parental Leave Rates Dropped Simultaneously
- Aiming for 22 Trillion Won with Just One Ring: The Secret Behind the Valuation Is 'Data' [Weekend Money]
- "V and Go Yoonjung Wear Them Too"... The Transformation of the ‘Grandma Ring’ Captivates Foreigners [K-Holic]
Verismo is currently conducting phase 1 clinical trials in the United States for the solid tumor CAR-T candidate 'SynKIR-110' and the hematological cancer CAR-T candidate 'SynKIR-310.' According to the company, initial interim results from SynKIR-110 were presented at the American Association for Cancer Research (AACR) conference in April, confirming safety and early signals of tumor reduction in the first three dose cohorts.
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.
